Uni-Bio Signs Up CR Zizhu To Market Recombinant Eye Treatment In China

Uni-Bio Science, a Hong Kong biopharma, signed an agreement that gives China Resources Zizhu Pharma China rights to market GeneSoft, an ophthalmic wound healing product. GeneSoft is a derivative of recombinant human epidermal growth factor (rhEGF), which improves healing of the cornea by regenerating the corneal epithelium. CR Zizhu, a wholly owned subsidiary of China Resource Pharma, focuses on the China hospital market for ophthalmology and reproductive health drugs. The initial term of the agreement is five years, with an option for an additional five years.